Trinka Vijmasi1, Feeling Y T Chen1, Suganthalakshmi Balasubbu1, Marianne Gallup1, Robert L McKown2, Gordon W Laurie3, Nancy A McNamara4. 1. Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States. 2. Department of Integrated Science and Technology, James Madison University, Harrisonburg, Virginia, United States. 3. Departments of Cell Biology and Ophthalmology, University of Virginia, Charlottesville, Virginia, United States. 4. Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, United States Departments of Anatomy and Ophthalmology, University of California San Francisco, San Francisco, California, United States School of Optometry and Vision Science Program, University of California, Berkeley, Berkeley, California, United States.
Abstract
PURPOSE: Lacritin is a tear glycoprotein with prosecretory, prosurvival, and mitogenic properties. We examined lacritin levels in the tears of Sjögren's syndrome (SS) patients and explored the therapeutic potential of topical lacritin for the treatment of keratoconjunctivitis sicca. METHODS: Tears from healthy controls (n = 14) and SS patients (n = 15) were assayed for lacritin using a C-terminal antibody. In a paired-eye study, autoimmune regulator (Aire) knockout (KO) mice (n = 7) were treated three times daily for 21 days with 10 μL of 4 μM lacritin (left eye) or vehicle (PBS) control (right eye). Tear secretion and ocular surface integrity were assessed at baseline and after treatment. Immunohistochemical staining of CD4+ T cells, cytokeratin-10 (K10), and cytokeratin-12 (K12) expression in the cornea and CD4+ T cell infiltration in the lacrimal glands were assessed. RESULTS: Lacritin monomer (421.8 ± 65.3 ng [SS] vs. 655.8 ± 118.9 ng [controls]; P = 0.05) and C-terminal fragment protein (125 ± 34.1 ng [SS] vs. 399.5 ± 84.3 ng [controls]; P = 0.008) per 100 μL of tear eluate were significantly lower in SS patients. In Aire KO mice treated with lacritin, tear secretion increased by 46% (13.0 ± 3.5 mm vs. 8.9 ± 2.9 mm; P = 0.01) and lissamine green staining score significantly decreased relative to baseline (-0.417 ± 0.06 vs. 0.125 ± 0.07; P = 0.02). Expression of K10 but not K12 in the cornea was significantly decreased in lacritin-treated eyes. Focal CD4+ T cell infiltration of the lacrimal glands was significantly reduced on the lacritin-treated side versus the untreated side. CONCLUSIONS: Lacritin is significantly reduced in the tears of SS patients. Topically administered lacritin has therapeutic potential for the treatment of aqueous-deficient dry eye disease. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE:Lacritin is a tear glycoprotein with prosecretory, prosurvival, and mitogenic properties. We examined lacritin levels in the tears of Sjögren's syndrome (SS) patients and explored the therapeutic potential of topical lacritin for the treatment of keratoconjunctivitis sicca. METHODS: Tears from healthy controls (n = 14) and SS patients (n = 15) were assayed for lacritin using a C-terminal antibody. In a paired-eye study, autoimmune regulator (Aire) knockout (KO) mice (n = 7) were treated three times daily for 21 days with 10 μL of 4 μM lacritin (left eye) or vehicle (PBS) control (right eye). Tear secretion and ocular surface integrity were assessed at baseline and after treatment. Immunohistochemical staining of CD4+ T cells, cytokeratin-10 (K10), and cytokeratin-12 (K12) expression in the cornea and CD4+ T cell infiltration in the lacrimal glands were assessed. RESULTS:Lacritin monomer (421.8 ± 65.3 ng [SS] vs. 655.8 ± 118.9 ng [controls]; P = 0.05) and C-terminal fragment protein (125 ± 34.1 ng [SS] vs. 399.5 ± 84.3 ng [controls]; P = 0.008) per 100 μL of tear eluate were significantly lower in SS patients. In Aire KO mice treated with lacritin, tear secretion increased by 46% (13.0 ± 3.5 mm vs. 8.9 ± 2.9 mm; P = 0.01) and lissamine green staining score significantly decreased relative to baseline (-0.417 ± 0.06 vs. 0.125 ± 0.07; P = 0.02). Expression of K10 but not K12 in the cornea was significantly decreased in lacritin-treated eyes. Focal CD4+ T cell infiltration of the lacrimal glands was significantly reduced on the lacritin-treated side versus the untreated side. CONCLUSIONS:Lacritin is significantly reduced in the tears of SS patients. Topically administered lacritin has therapeutic potential for the treatment of aqueous-deficient dry eye disease. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels Journal: Arthritis Care Res (Hoboken) Date: 2012-04 Impact factor: 4.794
Authors: Ying-Ting Chen; Stanislav Lazarev; Ahmad F Bahrami; Lisa B Noble; Feeling Y T Chen; Delu Zhou; Marianne Gallup; Mahesh Yadav; Nancy A McNamara Journal: Lab Invest Date: 2012-01-09 Impact factor: 5.662
Authors: Ying-Ting Chen; Karina Nikulina; Stanislav Lazarev; Ahmad F Bahrami; Lisa B Noble; Marianne Gallup; Nancy A McNamara Journal: Am J Pathol Date: 2010-08-09 Impact factor: 4.307
Authors: Francisco Velez V; Jeffrey A Romano; Robert L McKown; Kari Green; Liwen Zhang; Ronald W Raab; Denise S Ryan; Cindy M L Hutnik; Henry F Frierson; Gordon W Laurie Journal: Invest Ophthalmol Vis Sci Date: 2013-03-01 Impact factor: 4.799
Authors: Yinghui Zhang; Ningning Wang; Ronald W Raab; Robert L McKown; Jacob A Irwin; Inchan Kwon; Toin H van Kuppevelt; Gordon W Laurie Journal: J Biol Chem Date: 2013-03-15 Impact factor: 5.157
Authors: Mark D P Willcox; Pablo Argüeso; Georgi A Georgiev; Juha M Holopainen; Gordon W Laurie; Tom J Millar; Eric B Papas; Jannick P Rolland; Tannin A Schmidt; Ulrike Stahl; Tatiana Suarez; Lakshman N Subbaraman; Omür Ö Uçakhan; Lyndon Jones Journal: Ocul Surf Date: 2017-07-20 Impact factor: 5.033
Authors: Wan Wang; Aarti Jashnani; Suhaas R Aluri; Joshua A Gustafson; Pang-Yu Hsueh; Frances Yarber; Robert L McKown; Gordon W Laurie; Sarah F Hamm-Alvarez; J Andrew MacKay Journal: J Control Release Date: 2014-12-03 Impact factor: 9.776